https://oncdata.com/new-combination-approach-to-kmt2a-rearranged-infant-leukemiaOncology Data Advisoren2026-11-13T14:03:33.382ZA New Combination Approach to KMT2A-Rearranged Infant Leukemia https://oncdata.com/article/cd8bb946-2881-41fd-9ffe-5a96f549baaeOncology Data Advisoren2026-11-13T12:49:54.689ZPerioperative Camrelizumab (Investigational) With Chemotherapy Improves EFS in Resectable HNSCC https://oncdata.com/article/0590a61d-266b-4197-97c6-63ec39fc067aOncology Data Advisoren2026-11-13T12:49:54.486ZLong-Term Second Cancer Risks in Female Hodgkin Lymphoma Survivors Across Treatment Eras https://oncdata.com/article/a44f4ac1-3296-4898-9131-54948cdd3317Oncology Data Advisoren2026-11-12T22:49:17.075ZPrognostic Nomogram for Supratentorial H3 K27-Altered Diffuse Midline Glioma: IPD Meta-Analysis https://oncdata.com/article/6479ec08-1310-4728-b7ed-12f4e182b92dOncology Data Advisoren2026-11-12T12:49:44.695ZNo OS or PFS Advantage With Targeted Agents or Immunotherapy in Glioblastoma https://oncdata.com/article/007f2c14-275a-4f45-ad86-7af85d9b12bfOncology Data Advisoren2026-11-12T12:49:44.549ZPalbociclib Regimen in HR+/HER2+ Breast Cancer With Brain Metastases: Phase 2 Trial Results https://oncdata.com/article/ee5ebc20-0a45-4f31-a36c-f9b56025a143Oncology Data Advisoren2026-11-11T22:49:56.405ZPhase III DIAMOND-2 Trial: Dirozalkib vs Crizotinib in Advanced ALK-Positive NSCLC